Ascendis Pharma A (ASND) Change in Receivables (2014 - 2026)

Ascendis Pharma A has reported Change in Receivables for 13 years, with the latest figure at -$42.6 million in Q1 2026.

• Quarterly Change in Receivables fell 141.3% year-over-year to -$42.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.6 million (down 81.21% YoY) and the FY2025 annual result came in at $135.7 million, up 207.08% from the prior year.
• Change in Receivables fell to -$42.6 million in Q1 2026 per ASND's latest filing, from $106.5 million in the prior quarter.
• Over five years, Change in Receivables peaked at $106.5 million in Q4 2025 and troughed at -$133.4 million in Q4 2024.
• A 5-year average of -$5.3 million and a median of -$9.2 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables plunged 3786.48% in 2023, then soared 941.05% in 2025.
• Over 5 years, Change in Receivables stood at -$5.6 million in 2022, then sank by 64.71% to -$9.2 million in 2023, then sank by 1354.25% to -$133.4 million in 2024, then surged by 179.82% to $106.5 million in 2025, then slumped by 140.01% to -$42.6 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$42.6 million, $106.5 million, and -$29.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.